PURPOSE: A theoretical method has been devised for prediction of drug absorption after oral administration to humans. METHODS: Twenty structurally diverse model drugs, ranging from 0.3 to 100% absorbed, were investigated. The compounds also displayed diversity in physicochemical properties such as lipophilicity, hydrogen bonding potential and molecular size. The dynamic molecular surface properties of the compounds were calculated, taking into account their three-dimensional shape and flexibility. RESULTS: An excellent sigmoidal relationship was established between the absorbed fraction after oral administration to humans (FA) and the dynamic polar molecular surface area (PSAd) (r2 = 0.94). The relationship was stronger than those obtained for more established predictors of drug absorption. Drugs that are completely absorbed (FA > 90%) had a PSAd < or = 60 A2 while drugs that are < 10% absorbed had a PSAd > or = 140 A2. CONCLUSIONS: The results indicate that PSAd can be used to differentiate poorly absorbed drugs at an early stage of the drug discovery process.
PURPOSE: A theoretical method has been devised for prediction of drug absorption after oral administration to humans. METHODS: Twenty structurally diverse model drugs, ranging from 0.3 to 100% absorbed, were investigated. The compounds also displayed diversity in physicochemical properties such as lipophilicity, hydrogen bonding potential and molecular size. The dynamic molecular surface properties of the compounds were calculated, taking into account their three-dimensional shape and flexibility. RESULTS: An excellent sigmoidal relationship was established between the absorbed fraction after oral administration to humans (FA) and the dynamic polar molecular surface area (PSAd) (r2 = 0.94). The relationship was stronger than those obtained for more established predictors of drug absorption. Drugs that are completely absorbed (FA > 90%) had a PSAd < or = 60 A2 while drugs that are < 10% absorbed had a PSAd > or = 140 A2. CONCLUSIONS: The results indicate that PSAd can be used to differentiate poorly absorbed drugs at an early stage of the drug discovery process.
Authors: Yuan H Zhao; Michael H Abraham; Joelle Le; Anne Hersey; Chris N Luscombe; Gordon Beck; Brad Sherborne; Ian Cooper Journal: Pharm Res Date: 2002-10 Impact factor: 4.200
Authors: Kiyohiko Sugano; Manfred Kansy; Per Artursson; Alex Avdeef; Stefanie Bendels; Li Di; Gerhard F Ecker; Bernard Faller; Holger Fischer; Grégori Gerebtzoff; Hans Lennernaes; Frank Senner Journal: Nat Rev Drug Discov Date: 2010-08 Impact factor: 84.694